Retirement Systems of Alabama Acquires 108,759 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Retirement Systems of Alabama increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 128.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 193,101 shares of the medical equipment provider’s stock after purchasing an additional 108,759 shares during the quarter. Retirement Systems of Alabama owned 0.28% of Lantheus worth $17,275,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Wilmington Savings Fund Society FSB bought a new position in Lantheus during the 3rd quarter valued at about $25,000. Signaturefd LLC boosted its holdings in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the last quarter. UMB Bank n.a. raised its stake in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. purchased a new position in shares of Lantheus in the 3rd quarter worth $51,000. Finally, GAMMA Investing LLC boosted its stake in shares of Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 146 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Performance

LNTH opened at $90.90 on Friday. The firm’s fifty day moving average is $92.09 and its 200 day moving average is $99.04. The stock has a market cap of $6.32 billion, a price-to-earnings ratio of 15.12 and a beta of 0.44. Lantheus Holdings, Inc. has a fifty-two week low of $53.47 and a fifty-two week high of $126.89.

Insider Transactions at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on LNTH. Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.